000			03746nam a22003615i 4500
001			282855
003			MX-SnUAN
005			20160429154209.0
007			cr nn 008mamaa
008			150903s2008 ne | o |||| 0|eng d
020			_a9781402066863 _99781402066863
024	7		_a10.1007/9781402066863 _2doi
035			_avtls000335722
039		9	_a201509030240 _bVLOAD _c201404300306 _dVLOAD _y201402041307 _zstaff
040			_aMX-SnUAN _bspa _cMX-SnUAN _erda
050		4	_aR-RZ
100	1		_aSchulkin, Jay. _eautor _9309919
245	1	0	_aMedical Decisions, Estrogen and Aging / _cby Jay Schulkin.
264		1	_aDordrecht : _bSpringer Netherlands, _c2008.
300			_brecurso en línea.
336			_atexto _btxt _2rdacontent
337			_acomputadora _bc _2rdamedia
338			_arecurso en línea _bcr _2rdacarrier
347			_aarchivo de texto _bPDF _2rda
500			_aSpringer eBooks
505	0		_aHormone Therapy: Biological, Social, and Medical Context -- Demythologized Human Decision-Making -- Autonomic Regulation, Heart, and Strokes -- Bad News—Good News: Cancers and Bone -- Brain, Mood, and Cognition -- Physicians' and Women's Responses to HT Findings: Implications for Continuous Learning and Self-Corrective Inquiry for Physicians.
520			_aThe decision-making process that underlies ovarian hormone therapy (HT) is a fallible one. The question is whether or not physicians should prescribe HT to menopausal women, who are at a time in their lives when they are factoring various concerns into their decision to take (or not take) HT. Not only is it difficult to determine whether or not to prescribe HT, but what kind; should physicians recommend estrogen or progestin, or another combination of related hormones? The decision of whether or not to use HT has affected, and will continue to affect, many women in the United States and throughout the world and is an important model elucidating the forces that influence medical decision-making. Two recent large-scale studies, one conducted here in the United States (the Women’s Health Initiative) and the other in Great Britain (the Million Women Study), were highly publicized and cast a negative light on the use of HT. Since HT’s inception, views have oscillated, due in part to expectations of benefits extending over the course of long-term use beyond the peri-menopausal period, and perhaps due to the overselling of research investigating the efficacy of HT. Thus, the decision for women to go on HT remains a controversial issue, and the decision-making process is undermined further by overzealous advertising and an exaggerated understanding of the research results (both positive and negative). This book is unique in that it integrates core findings from within the Decision Sciences and Evidence Based Medicine in light of the research that has been done on HT. Medical Decisions, Estrogen and Aging integrates the various components that go into medical decision making in the context of understanding the dilemmas that surround HT. Therefore this book is intended for both specialists and generalists in the field, and it is ideally suited for use by graduate and medical students, medical health care professionals, behavioral scientists, medical ethicists, gerontologists, historians of science, and endocrinologists.
590			_aPara consulta fuera de la UANL se requiere clave de acceso remoto.
710	2		_aSpringerLink (Servicio en línea) _9299170
776	0	8	_iEdición impresa: _z9781402066856
856	4	0	_uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-1-4020-6686-3 _zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942			_c14
999			_c282855 _d282855